HCPCS Level IIdrugActive
J0593
Inj., lanadelumab-flyo, 1 mg
BETOS: O1E
Effective: 2024-01-01
Description
Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Takhzyro
Manufacturer
Takeda Pharmaceuticals America, Inc.
HCPCS Dosage
1 MG
Billing Units
300.0000
3
NDC Products
asp
Pricing Source